ClinicalTrials.Veeva

Menu

Multifocal High ADD Contact Lens Proof of Concept Trial

Alcon logo

Alcon

Status

Completed

Conditions

Presbyopia

Treatments

Device: Lotrafilcon B multifocal contact lenses (new)
Device: Lotrafilcon B multifocal contact lenses

Study type

Interventional

Funder types

Industry

Identifiers

NCT02117544
C-13-057

Details and patient eligibility

About

The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.

Enrollment

268 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Must sign an Informed Consent document;
  • Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
  • Current or previous soft contact lens wearer;
  • Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) [Early Treatment of Diabetic Retinopathy Study (ETDRS)] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
  • Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
  • Manifest cylinder less than or equal to 1.00 D;
  • Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
  • Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
  • Any history of herpetic keratitis;
  • History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
  • Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
  • Corneal vascularization that is mild (Grade 2) or higher;
  • A pathologically dry eye that precludes contact lens wear;
  • Monocular (only 1 eye with functional vision);
  • Anisometropia ≥ 1.50 D (contact lens distance prescription);
  • Clinically significant (> 1 millimeter) anisocoria;
  • History of intolerance or hypersensitivity to any component of the investigational products;
  • Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
  • Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
  • Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
  • Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

268 participants in 2 patient groups

New MF, then AOAMF
Other group
Description:
Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
Treatment:
Device: Lotrafilcon B multifocal contact lenses
Device: Lotrafilcon B multifocal contact lenses (new)
AOAMF, then New MF
Other group
Description:
Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
Treatment:
Device: Lotrafilcon B multifocal contact lenses
Device: Lotrafilcon B multifocal contact lenses (new)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems